Access
This article is part of Nature's premium content.
Published online 29 April 2009 | Nature | doi:10.1038/news.2009.414
News
Controversial vaccine fights prostate cancer
Provenge results could be a shot in the arm for a struggling field.
A vaccine designed to fight prostate cancer significantly increased survival in a critical large clinical trial, investigators reported yesterday.
The vaccine, called Provenge (sipuleucel-T), trains the immune system to recognize and fight off prostate cancer cells.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email webadmin@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.
There are currently no comments.
